Ann Surg Oncol

1. AYUB S, Marra A, Liu Y, Postlewait LM, et al
   Rurality and Income on Breast Cancer Outcomes: An Analysis of the SEER Database.
   Ann Surg Oncol. 2026 Feb 19. doi: 10.1245/s10434-026-19254.
   

   >> Share

   
   
2. RODRIGUEZ L, Wu R, Kassi A, Ishikawa T, et al
   High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer.
   Ann Surg Oncol. 2026 Feb 19. doi: 10.1245/s10434-026-19133.
   

   >> Share

   
   
3. KINOSHITA T, Takayama S, Fujisawa T, Watanabe K, et al
   Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409).
   Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19220.
   

   >> Share

   
   
4. PUJOL N, Gal J, Gautier M, Rizzi Y, et al
   Second Ipsilateral Breast Cancer Event: True Recurrence, New Primary, or True Recurrence Like? : Breast Cancer Local Recurrence.
   Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19131.
   

   >> Share

   
   
5. SCHRANK Z, Selfridge JM
   ASO Author Reflections: Do Older Triple-Negative Breast Cancer Patients Respond Differently to Neoadjuvant Chemoimmunotherapy?
   Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19299.
   

   >> Share

   
   
6. ABDULLA HA, McGarry J, Kaczorowska R, Grealish A, et al
   ASO Visual Abstract: Oncological Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection in Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-analysis.
   Ann Surg Oncol. 2026 Feb 18. doi: 10.1245/s10434-026-19273.
   

   >> Share

   
   
7. JAYASWAL RP
   Letter Comments on: Differences in Breast Cancer Care Between Rural Women Undergoing Treatment at a Referral Center and Those Treated Locally.
   Ann Surg Oncol. 2026 Feb 17. doi: 10.1245/s10434-026-19258.
   

   >> Share

   
   
8. RYU HH, Lee YJ, Yoo TK, Kim J, et al
   Clinical Utility of Oncotype DX Testing in Synchronous Bilateral and Unilateral Multifocal Breast Cancer.
   Ann Surg Oncol. 2026 Feb 16. doi: 10.1245/s10434-026-19243.
   

   >> Share

   
   

   
   BMC Cancer

9. DENG Y, Huang W, Zeng T, Gao Y, et al
   CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.
   BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15713.
   

   >> Share

   
   
10. BROWNSON-SMITH R, Carr J, Orange ST, Cresti N, et al
    Longitudinal assessment of chemotherapy-induced peripheral neuropathy in women undergoing taxane-based treatment for breast cancer: a prospective observational study.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15750.
    

    >> Share

    
    
11. EDET B, Sarimiye FO, Essien E, Lu B, et al
    A cross-sectional study of coping strategies among a sample of women with breast cancer in South-South, Nigeria.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15770.
    

    >> Share

    
    
12. HOSSAIN I, Ivy SC, Islam MS, Shahriar M, et al
    Evaluation of ERCC4 (XPF) gene rs6498486 polymorphism and its potential role in breast cancer risk among Bangladeshi women.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15739.
    

    >> Share

    
    

    
    Breast Cancer

13. PANG J, Huang B, Yan W, He H, et al
    Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based study.
    Breast Cancer. 2026 Feb 16. doi: 10.1007/s12282-026-01836.
    

    >> Share

    
    

    
    Breast Cancer Res

14. ALDRICH MB, McWain ME, Shaitelman SF, Kuhns RE, et al
    Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.
    Breast Cancer Res. 2026 Feb 17. doi: 10.1186/s13058-026-02231.
    

    >> Share

    
    
15. BREMER T, Mittal K, Shah C, Vicini F, et al
    Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients.
    Breast Cancer Res. 2026 Feb 18. doi: 10.1186/s13058-026-02237.
    

    >> Share

    
    
16. DEHGHAN MANSHADI M, Hashemi F, Safaei S, Golshahi H, et al
    Prophylactic and therapeutic CSC-based vaccination reduced tumor growth, metastasis and enhanced survival in mouse model of breast cancer.
    Breast Cancer Res. 2026 Feb 19. doi: 10.1186/s13058-026-02242.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

17. TSE SSW, Wong HCY, Charbonneau F, Cao JQ, et al
    Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective.
    Breast Cancer Res Treat. 2026;216:10.
    

    >> Share

    
    
18. SOYANO MULLER AE, Goodridge DN, Mo Q, Whiting J, et al
    Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2026;216:11.
    

    >> Share

    
    
19. SHINN E, Zahrieh D, DeMichele A, Zdenkowski N, et al
    Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
    Breast Cancer Res Treat. 2026;216:12.
    

    >> Share

    
    
20. VASIGH M, Williams AD, Hasler JS, Aggon A, et al
    The role of regional nodal irradiation in clinically node-positive breast cancer patients who undergo neoadjuvant chemotherapy and breast-conserving surgery.
    Breast Cancer Res Treat. 2026;216:14.
    

    >> Share

    
    

    
    Cancer

21. LAWRENCE L
    TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer: Almost a 3-month improvement was seen in median PFS for patients assigned to sacituzumab govitecan in comparison to those assigned to chemothera
    Cancer. 2026;132:e70249.
    

    >> Share

    
    
22. LIPSCOMB J, Kimmick GG, Wilson JF, Currey A, et al
    Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.
    Cancer. 2026;132:e70267.
    

    >> Share

    
    

    
    Cancer Lett

23. ZHAO Z, Jia W, Li Z, Shi S, et al
    Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 Axis Disrupts Metabolic-Epigenetic Crosstalk and Suppresses Progression in Hyperglycolytic Breast Cancer.
    Cancer Lett. 2026 Feb 16:218328. doi: 10.1016/j.canlet.2026.218328.
    

    >> Share

    
    
24. XUE X, Ji D, Xue L, Tan Y, et al
    Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE Trial.
    Cancer Lett. 2026 Feb 18:218327. doi: 10.1016/j.canlet.2026.218327.
    

    >> Share

    
    

    
    Cell

25. BARKI D, Eilat N, Scherz-Shouval R
    Striking a nerve: Sensory neurons orchestrate ECM remodeling and immune exclusion in TNBC.
    Cell. 2026;189:993-994.
    

    >> Share

    
    

    
    Clin Breast Cancer

26. MIYASHITA H, Aoshima K
    Predicting Skeletal-Related Events in Bone Metastasis from Advanced Breast Cancer Using Machine Learning.
    Clin Breast Cancer. 2026 Jan 12:S1526-8209(26)00004.
    

    >> Share

    
    
27. AU LJ, Zhang YN, Yeung K, Cheung KL, et al
    Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis.
    Clin Breast Cancer. 2026;26:84-93.
    

    >> Share

    
    

    
    Eur Radiol

28. EOM HJ, Kim HH, Kim SH, Gwon HY, et al
    Implant-displacement views alone for breast cancer screening in women with implants: a multicenter retrospective study.
    Eur Radiol. 2026 Feb 20. doi: 10.1007/s00330-026-12374.
    

    >> Share

    
    

    
    Int J Oncol

29. LIU J, Du H, Shi Y
    Role and underlying mechanisms of miR?200 family in breast cancer (Review).
    Int J Oncol. 2026;68:43.
    

    >> Share

    
    

    
    J Clin Invest

30. YU L, Rivas C, Liu F, Shen Y, et al
    Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer.
    J Clin Invest. 2026 Feb 17:e198815. doi: 10.1172/JCI198815.
    

    >> Share

    
    

    
    J Natl Cancer Inst

31. DANIELSSON O, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
    J Natl Cancer Inst. 2026 Feb 19:djag049. doi: 10.1093.
    

    >> Share

    
    
32. TICKLE A, Offman J, North B, Jorgensen SF, et al
    Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study.
    J Natl Cancer Inst. 2026 Feb 19:djaf377. doi: 10.1093.
    

    >> Share

    
    
33. KORIC A, Bennett DL, Boulos F, Colditz GA, et al
    Subsequent breast cancer risk after benign biopsy in racially diverse women: Siteman Cancer Center.
    J Natl Cancer Inst. 2026 Feb 16:djag048. doi: 10.1093.
    

    >> Share

    
    

    
    Lancet Oncol

34. LOUIS FM, van der Voort A, van Ramshorst MS, Daletzakis A, et al
    MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00707.
    

    >> Share

    
    
35. NADER-MARTA G, Mayer EL
    Towards response-adapted neoadjuvant breast cancer treatment.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00767.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

36. KILLOCK D
    CDK4/6 inhibition provides additional efficacy in HER2(+), HR(+) breast cancer.
    Nat Rev Clin Oncol. 2026 Feb 17. doi: 10.1038/s41571-026-01133.
    

    >> Share

    
    

    
    Nature

37. 
    Personalized mRNA vaccine induces strong, durable immunity in hard-to-treat breast cancer.
    Nature. 2026 Feb 18. doi: 10.1038/d41586-026-00477.
    

    >> Share

    
    
38. HAN Y, Ma Y, Pei M, Yin S, et al
    Intratumoural vaccination via checkpoint degradation-coupled antigen presentation.
    Nature. 2026;650:736-747.
    

    >> Share

    
    

    
    NPJ Breast Cancer

39. XU T, Gu Q, Li S, Zhang L, et al
    Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling.
    NPJ Breast Cancer. 2026 Feb 17. doi: 10.1038/s41523-026-00914.
    

    >> Share

    
    
40. ZELS G, Van Baelen K, Chang AC, Pabba A, et al
    Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs.
    NPJ Breast Cancer. 2026 Feb 20. doi: 10.1038/s41523-026-00912.
    

    >> Share

    
    

    
    Oncogene

41. MA L, Sheng X, Wang L, Wan X, et al
    KDM6A alternative splicing induced by 25(OH)D inhibits breast cancer cell stemness through repressing TRAP1 transcription.
    Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03694.
    

    >> Share

    
    
42. SZYMANSKI L, Schenk T, Lawinski M, Brioli A, et al
    Association of retinoids, retinoic acid receptors and epigenetics in breast cancer.
    Oncogene. 2026 Feb 20. doi: 10.1038/s41388-026-03699.
    

    >> Share

    
    

    
    Oncol Rep

43. YUAN Z, Sanders AJ, Ye L, Wang Y, et al
    [Retracted] Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP?9.
    Oncol Rep. 2026;55:73.
    

    >> Share

    
    

    
    Oncology (Williston Park)

44. POLAND S, de Oliveira Andrade Md M, Nanda R
    Advances in Immunotherapy for Breast Cancer.
    Oncology (Williston Park). 2026;40:8-15.
    

    >> Share

    
    

    
    PLoS Comput Biol

45. WANG Y, Zang C, Li Z, Guo CC, et al
    A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics.
    PLoS Comput Biol. 2026;22:e1013956.
    

    >> Share

    
    

    
    PLoS One

46. ALQAHTANI S, Alqahtani K, Alshomrani F, AlQahtani K, et al
    AdaptiveInvolutionNet: Spatially-adaptive involution with channel-wise attention for breast MRI tumor classification.
    PLoS One. 2026;21:e0340808.
    

    >> Share

    
    
47. XU F, Xie S, Li Q, Zhong X, et al
    The effect of self-concealment on post-traumatic stress symptoms in breast cancer patients: The mediating role of experiential avoidance.
    PLoS One. 2026;21:e0342971.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

48. LOU KL, Bai JW, Liu HT, Lin LL, et al
    TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers.
    Proc Natl Acad Sci U S A. 2026;123:e2519420123.
    

    >> Share

    
    
49. YAN P, Bui T, Rojas Jimenez E, Kuang Y, et al
    Aging-associated differences in mammary tumor-initiating populations and immune evasion pathways in breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2523254123.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share